All News
#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p
Dr. Rachel Tate uptoTate ( View Tweet)
Are we asking women with IPAF about family planning?
Abstract #0944 #ACR22 @RheumNow
🫁 31 women
🤰83% had RF for adverse pregnancy outcomes
👼1/3 women had family plan. or birth control talks with pulm. docs
✋>50% women who saw a rheumatologist discussed these topics
Catherine Sims, MD DrCassySims ( View Tweet)
Rheum/ILD combined clinics may help dx ILD assoc'd CTD that is underdiagnosed currently. Pic below is very informative! Abs 1874 #ACR22 @RheumNow https://t.co/rr0QEfqicv https://t.co/V6eTyz1BuV
Dr. Rachel Tate uptoTate ( View Tweet)
Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT https://t.co/CqK0dL7DQK
Dr. Rachel Tate uptoTate ( View Tweet)
#abst2109 #ACR22 @RheumNow GO-VIBRANT bio-naïve pts w/active PsA Rx w/IV GLM tend respond slower in all domains if ⬆️ age, HAQ-DI score, and spinal pain; smoking gives w/lower odds of HAQ-DI ≤0.5 at W52. minimal SJC& ⬇️enthesitis achieved significantly faster than TJC, HAQ-DI https://t.co/qqmjEAq3Cd
Olga Petryna DrPetryna ( View Tweet)
#ACR22 Abstr#L08 Is Evusheld effective in the first 6 mths of therapy in #COVID Omicron era? A cohort study of 157 RMD patients who were fully vaccinated reported 24 (15%) breakthrough infection; only 2 (1%) required hospitalisation. COVID occurred ~3mths post-therapy @RheumNow https://t.co/VJogB2otbn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Possible new biomarker in early RA? RA patients with high level of measurable fibrogenesis (PRO-C3 serum levels) less likely to respond to TCZ, as compared to patients with low level of fibrogenesis. Abs 1986 #ACR22 @RheumNow https://t.co/xnyoV2xbWq https://t.co/Vka8UZsrar
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow #ACR22 https://t.co/dO7xDTApqP
Olga Petryna DrPetryna ( View Tweet)
Immunosuppressants (eg. MTX, RTX, MMF) can reduce immunogenicity to vaccines. VACIMRA study showing no difference in disease activity (beyond 1 month) and damage when MTX initiation was delayed by 1 month for the PCV13 pneumococcal vaccine.
@RheumNow ABST1960 #ACR22 https://t.co/SKQ2qx3lJG
Julian Segan JulianSegan ( View Tweet)
💤Our PsA patients are not sleeping well 💤
Abstract #0387 #ACR22 @RheumNow
😴 247 patients, sleep quality measured via PSQI
🛌 63% had poor sleep quality
💤 Worse sleep associated with female sex, higher disease activity, fatigue, anxiety/depression https://t.co/Wy20qx2Ah4
Catherine Sims, MD DrCassySims ( View Tweet)
To taper or not to taper?
In this prospective study by Dr. Cho, #SLE patients in complete remission had a longer time to flare upon drug tapering vs. those in LLDAS or clinical remission states.
#ACR22 @RheumNow ABST#0996 #ACRBEst @rheumarhyme https://t.co/bSGlkc7Tvk
sheila RHEUMarampa ( View Tweet)
#ACR22 Abs 1752 finds rates of incident cancer did not differ between patients treated with anti-TNF and other bDMARDs or tsDMARDs. @RheumNow https://t.co/ycnQzrmAjw https://t.co/CSgDq2Gazg
Dr. Rachel Tate uptoTate ( View Tweet)
Abs 1757 at #ACR22 finds women w/ gout have a higher risk of all-cause mortality, which is primarily driven by higher risk of CVD deaths. @RheumNow https://t.co/kPDL2VYRCN https://t.co/9qARr7T4fI
Dr. Rachel Tate uptoTate ( View Tweet)
Abs L04 reviews novel humanized murine model of PsA disease phenotypes mediated by CD8 T Cells. Perhaps this is a step forward in personalized medicine. #ACR22 @RheumNow https://t.co/fPoElqFLI7 https://t.co/4pxBKoPnym
Dr. Rachel Tate uptoTate ( View Tweet)
Prof Petri presents mortality data of their #lupus cohort
🔅55 yrs - ave age of death from all causes
Top 4 common causes of death:
🔅SLE
🔅CVD
🔅Cancer
🔅Infection
African-americans had ⬆️proportions of death from infections & renal causes
#ACR22 @RheumNow #ABST2068 https://t.co/B5cAfZiRJp
sheila RHEUMarampa ( View Tweet)
Is sustained B cell depletion assoc w/⬇️dse flares in #lupus nephritis?
In this study by Dr D Zisa, pts treated w/ BCA & had sustained Bcell depletion = ⬇️dse flares
👉Rapid repletion to BCC>100c/uL was assocd w/ 15.2x risk for flares
#ACR22 @RheumNow ABST2065 https://t.co/ivSjm98YvZ
sheila RHEUMarampa ( View Tweet)
Is there a difference between IL-17i and TNFi in preventing radiographic progression in radiographic axSpA?
Head to head study secukinumab vs. adalimumab biosimilar shows no sig difference with low radiographic progression.
#ACRBest Abs#L15 @RheumNow #ACR22 https://t.co/UiHMtakaPz
Robert B Chao, MD doctorRBC ( View Tweet)
Clinical pearl! Abs 1790 at #ACR22 finds bilateral US assessment of knees, wrists and hips provided the best sensitivity and specificity for diagnosing CPPD. @RheumNow https://t.co/3zlrNGCek4 https://t.co/hPK3eMH6iY
Dr. Rachel Tate uptoTate ( View Tweet)
Are we screening & tx approp. for HBV in #IIM?
Abstr #1864 found:
- 78% IIM pts were screened for HBV (mean time 21 months from time of dx)
- 73% Hep B Core Ab+ on RTX received Ppx tx
- IIM pts Hep B Core Ab+ ↑ % +myositis spec ab and reach remission w/ IVIG
@RheumNow #ACR22 https://t.co/QlQxGlkIhh
Akhil Sood MD AkhilSoodMD ( View Tweet)
Denosumab for erosive hand OA? Abs L05 shows less erosive progression at week 24 with enhancement, including pain symptom improvement, at week 48. I can't wait to see more on this! #ACRbest #ACR22 @RheumNow https://t.co/aYb1biVgqt https://t.co/xHXj7nu1IJ
Dr. Rachel Tate uptoTate ( View Tweet)